Dyslipidemia is closely related to cardiovascular disease. In the past 10 years, a series of milestone blood lipid intervention studies have been completed at home and abroad. These results strongly confirm that actively lowering cholesterol levels can significantly reduce the incidence of cardiovascular events in high-risk groups of cardiovascular diseases, so lowering cholesterol to achieve the standard is regarded as the core strategy for the prevention and treatment of cardiovascular diseases. Although there is conclusive evidence that statins play an important role in the primary and secondary prevention of atherosclerotic cardiovascular diseases, and the rational use of such drugs can significantly reduce the morbidity and mortality of cardiovascular diseases. However, in clinical practice, many patients' cholesterol levels still can't reach the target value after receiving larger doses of statin therapy, and some patients can't tolerate statin therapy for various reasons, which has become an important obstacle to improve the compliance rate of blood lipids. The results of the second survey on the status of blood lipid therapy in China show that the compliance rate of LDL-C in patients with high-risk and extremely high-risk cardiovascular diseases is only 31% and 22%. This situation suggests that we should take more effective measures to intervene on cholesterol levels, in order to bring as many clinical benefits to patients as possible. The advent of new cholesterol-lowering drugs, selective cholesterol absorption inhibitors, provides a new method for cholesterol-lowering therapy.
